Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
15 drugs in development
By Therapeutic Area
top 1
R&D Momentum
87/100
Pipeline Velocity
65/100
Trial Completion Rate
72/100
Pipeline Concentration
50/100
Pipeline Freshness
67/100
Strategic Signals
Activity
Last 14 days
TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE-BDT)
Feasibility of a Digital Art Therapy Application Designed to Improve Quality of Life in Young Cancer Survivors
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma
PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study
Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)
Keep Social Randomized Controlled Trial for Young Adults With Cancer
Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors
Carolina Breast Cancer Study: Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes in the Carolina Breast Cancer Study, Phase 4
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)